According to the doctors, the patient affected by RSV will have a cough and cold in the first two days and then they will develop breathing problems, and, in some cases, it turns out to be serious.
The antibody responses in the participants given 10 microgram doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with 30 microgram doses.
Copyright © 2024 - Odisha Television Limited All Rights Reserved.